Shots:

• The P-II/III study involves assessing of Troriluzole (qd- PO) vs PBO in 350 patients with mild to mod. AD for up to 48wks.
• The study missed its co-primary endpoints i.e. ADAS-cog & CDR-SB. The therapy also failed to beat PBO on the 2EPs of hippocampal volume assessed by MRI in the overall population
• A subgroup analysis of mild AD patients unveils that troriluzole exhibited a nonsignificant numerical difference of a potential benefit @48wks. on both the ADAS-cog and hippocampal volumetric MRI. Further- secondary & exploratory efficacy analyses and biomarker data including NfL- neurogranin- tau and amyloid are still pending and are expected in the coming mos.

 ­ Ref: Biohaven | Image: Biohaven